Archive
561 articles, sorted by publication time.
GLP-1 drugs have reshaped diabetes and weight-loss treatment, but a study spanning human, animal, and clinical trial data offers a reminder: differences in efficacy may not be only a matter of willpower or dose, but may also lie in genes that regulate incretin signaling.
This early trial pushes the vaccine strategy from “chasing variants with updates” toward a defense aimed at an entire virus family; immune responses have been observed, but true protection still awaits answers from larger studies.
A retrospective study of more than 110,000 women has pushed popular metabolic drugs into the center of discussions about cancer prevention; the signal is clear, but answers remain early, and the next step will depend on prospective trials to distinguish the true relationship among drugs, weight, and cancer risk.
The approval moves treatment for severe LAD-I toward autologous hematopoietic stem cell gene repair, but clinical benefit still needs answers from long-term follow-up and postmarketing studies.
An ETH Zurich team has shifted attention to the GRK2 protein, which aggregates uncontrollably inside brain cells, and used an experimental compound to block a cascade of damage in mice; this is not proof of clinical efficacy, but it adds a new path for Alzheimer’s drug development that warrants serious testing.
A small group of DNA regulatory regions that do not encode proteins may have laid the underlying neurodevelopmental conditions for language ability before modern humans and Neanderthals split.
A mouse study from Scripps Research shows that an experimental vaccine can induce antibodies to intercept fentanyl and multiple variants, offering a preventive vision for overdose risk; but it still faces questions of clinical trials, target populations, and public health deployment before human use.
Life Biosciences is advancing partial cellular reprogramming into human safety testing, targeting glaucoma and ischemic optic neuropathy; the step is important, but there remains a scientific and regulatory path before vision restoration is proven.
A gene once viewed mainly as immune-related has now been linked to disrupted neural signaling and spastic ataxia; the finding is a reminder that, in rare disease diagnosis, the answer is sometimes not on the familiar candidate list.
Archaic human fragments in the genomes of Pacific populations bring a long-ago history of interbreeding to the surface; it is not only an evolutionary footnote, but may also change how modern humans respond to infection and immune pressure.
Nature Biotechnology has published an author correction fixing misplaced chart data in a study of dephospho-CoA-capped RNA. The conclusions were not overturned, but the credibility of such emerging transcriptome measurement technologies is being built on repeated calibration with traceable details.
Site4Drug attempts to make "target-site selection" no longer just a black-box intuition: it organizes protein topology, accessibility, and chemical constraints into traceable judgments, but for now it remains a method proposal at the preprint stage, with validation still needed before it can become a drug development decision-making tool.